| 前收市價 | 112.36 |
| 開市 | 112.36 |
| 買盤 | 110.83 x 42300 |
| 賣出價 | 117.96 x 43500 |
| 今日波幅 | 112.36 - 112.36 |
| 52 週波幅 | 86.12 - 119.65 |
| 成交量 | |
| 平均成交量 | 15,338 |
| 市值 | 141.856B |
| Beta 值 (5 年，每月) | 0.42 |
| 市盈率 (最近 12 個月) | 30.39 |
| 每股盈利 (最近 12 個月) | 3.70 |
| 業績公佈日 | 2024年10月25日 |
| 遠期股息及收益率 | 4.07 (3.62%) |
| 除息日 | 2024年5月13日 |
| 1 年預測目標價 | 無 |
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
Motley FoolShould You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough?
BloombergCD&R in Talks With Banks Over Debt to Fund Equity for Sanofi Arm
(Bloomberg) -- Clayton Dubilier & Rice is discussing the possibility of using borrowed money to fund a part of the equity check in its bid for Sanofi’s €15 billion ($16.6 billion) consumer health division, according to people familiar with the matter.Most Read from BloombergHousing’s Worst Crisis in Decades Reverberates Through 2024 RaceFrom Louisville, a Push to Plant Trees for Public HealthUS Driving and Congestion Rates Are Higher Than EverAn Affordable Nomadic Home Design Struggles to Adapt
